Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 14/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 14/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.58 |
| ▸ | CNR2 | P34972 | 2/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | CASR | P41180 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10052083 | 0.84 | CA2 (0.47) | — | |
| SCHEMBL29143285 | 0.80 | HTR7 (0.51) | GABRA1GABRB2ALOX5CNR2HTR7 | |
| SCHEMBL18780832 | 0.79 | GABRA1 (0.60) | GABRA1GABRB2ALOX5CNR2GABRA5 | |
| SCHEMBL30728864 | 0.78 | PDE4B (0.56) | GABRA1GABRB2ALOX5CNR2HTR7 | |
| SCHEMBL15906086 | 0.78 | SMN1; SMN2 (0.45) | GABRA1GABRB2ALOX5CNR2HTR7 | |
| SCHEMBL28008884 | 0.77 | KDM4E (0.46) | GABRA1GABRB2ALOX5CNR2HTR7 | |
| SCHEMBL3466479 | 0.77 | PDE4B (0.60) | GABRA1GABRB2ALOX5CNR2HTR7 | |
| SCHEMBL31060931 | 0.76 | GABRA1 (0.79) | GABRA1GABRB2ALOX5CNR2GABRA5 | |
| SCHEMBL10972502 | 0.75 | NAAA (0.51) | GABRA1GABRB2ALOX5CNR2CASR | |
| SCHEMBL1704704 | 0.74 | GABRA1 (0.63) | GABRA1GABRB2ALOX5CNR2GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3364957-B1 | IMPROVED SYNTHESIS OF HONOKIOL | COLGATE PALMOLIVE CO (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3364957-B1 | IMPROVED SYNTHESIS OF HONOKIOL | COLGATE PALMOLIVE CO (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3364957-A1 | IMPROVED SYNTHESIS OF HONOKIOL | Colgate-Palmolive Company (US) | 2018-08-29 | — | — | EP | disclosed |
| US-10053406-B2 | Synthesis of honokiol | COLGATE-PALMOLIVE COMPANY (US) | 2018-08-21 | — | — | US | disclosed |
| WO-2017070568-A1 | IMPROVED SYNTHESIS OF HONOKIOL | COLGATE-PALMOLIVE COMPANY (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070568-A1 | IMPROVED SYNTHESIS OF HONOKIOL | COLGATE-PALMOLIVE COMPANY (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20170113989-A1 | SYNTHESIS OF HONOKIOL | COLGATE-PALMOLIVE COMPANY | 2017-04-27 | — | — | US | disclosed |
| US-20170113989-A1 | SYNTHESIS OF HONOKIOL | COLGATE-PALMOLIVE COMPANY | 2017-04-27 | — | — | US | disclosed |
| US-20170113989-A1 | SYNTHESIS OF HONOKIOL | COLGATE-PALMOLIVE COMPANY | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170113989-A1 | SYNTHESIS OF HONOKIOL | UGT2B7, UGT1A7, DHCR7 | GABRA1 395/4885GABRB2 320/4885ALOX5 374/4885 |
| US-10053406-B2 | Synthesis of honokiol | UGT2B7, UGT1A7, DHCR7 | GABRA1 395/4885GABRB2 320/4885ALOX5 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.